Allurion Technologies (ALUR) announced its intention to initiate a clinical study on the combination of the Allurion Balloon with GLP-1 ...
Allurion Technologies, Inc. ("Allurion" or the "Company") , a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the Allurion Balloon ...
Allurion Technologies (ALUR) announced that it is relaunching the Allurion Balloon in France after ANSM, the French regulatory authority, ...
Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced that it is relaunching the Allurion Balloon in France after ANSM, the ...
Allurion Technologies today announced the relaunch of its Allurion Balloon in France following regulatory clearance to resume ...
Allurion Technologies Inc. is cleared by regulators in France to resume sales of its swallowable gastric balloon to treat ...
NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced ...
Company considering sites in France for clinical trial on combination therapy of Allurion Balloon and GLP-1s to prevent muscle loss Allurion Technologies, Inc. (“Allurion” or the “Company ...
The company plans to evaluate its Allurion Program with GLP-1 agonists to address muscle loss concerns and promote healthier weight loss. Allurion entered into a securities purchase agreement to ...